呋喹替尼联合雷替曲塞治疗晚期化疗耐药结直肠癌的临床疗效观察

Clinical efficacy of fuquintinib combined with rhatitrexed in the treatment of advanced chemotherapy-resistant colorectal cancer

摘要:

目的 探讨呋喹替尼联合雷替曲塞治疗晚期化疗耐药结直肠癌（CRC）的临床疗效。方法 选取2021年1月-2022年12月马鞍山市人民医院肿瘤科收治的80例晚期CRC患者，按照随机数字表法分为观察组和对照组，每组40例。对照组采用呋喹替尼靶向治疗；观察组在对照组基础上加用雷替曲塞治疗。对比两组临床疗效。结果 观察组疾病控制率、客观缓解率均高于对照组（P <0.05）。观察组治疗前后癌胚抗原、糖类抗原199、糖类抗原CA72-4差值均高于对照组（P <0.05）。观察组治疗前后卡氏功能状态评分差值低于对照组（P <0.05），简明疲乏量表评分差值高于对照组（P <0.05）。观察组与对照组高血压、蛋白尿、手足综合征、血小板减少、肝功能转氨酶升高发生率比较，差异均无统计学意义（P >0.05）。观察组白细胞减少发生率高于对照组（P <0.05）。两组患者随访1年，因联系方式丢失脱落6例，观察组与对照组最终随访各37例。观察组与对照组生存率比较，差异无统计学意义（P >0.05）。结论 采用呋喹替尼联合雷替曲塞治疗晚期化疗耐药CRC患者疗效显著，可显著提升患者生活质量，降低患者疲乏感，改善肿瘤标志物水平，1年生存率较高。

Abstract:

Objective To analyze the clinical efficacy of fuquinitinib combined with raltitrexed in the treatment of advanced chemotherapy-resistant colorectal cancer (CRC).Methods A total of 80 patients with advanced CRC who were admitted to the Oncology Department of Maanshan People's Hospital from January 2021 to December 2022 were selected. According to the random number table method, 40 cases were divided into two groups, the control group was treated with fuquinitinib targeted therapy, and the observation group was treated with rhatitrexed on the basis of the control group, and the efficacy was compared.Results The disease control rate rate and objective response rate rate of observation group were higher than those of control group (P <0.05). The differences of CEA, CA199 and CA72-4 in the observation group before and after treatment were higher than those in the control group (P <0.05). The difference of Knicks functional status score before and after treatment in the observation group was lower than that in the control group (P <0.05), and the difference of Concise Fatigue Scale score was higher than that in the control group (P <0.05). There was no significant difference in the incidence of hypertension, proteinuria, hand-foot syndrome, thrombocytopenia and elevated liver function aminotransferase between the observation group and the control group (P >0.05). There was significant difference in the incidence of leukopenia between the observation group and the control group (P >0.05). The incidence of leukopenia in observation group was higher than that in control group (P <0.05). Patients in the two groups were followed up for 1 year, 6 cases fell off due to contact information loss, 37 cases in the observation group and 37 cases in the control group completed the final follow-up. There was no significant difference in survival rate between the observation group and the control group (P >0.05).Conclusion Fuquitinib combined with raltitrexed in the treatment of advanced chemotherapy-resistant CRC patients is effective, can significantly improve the quality of life of patients, reduce fatigue, improve tumor markers, and have a high 1-year survival rate.